A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

December 21, 2012

New HIV Vaccine Is Safe and Boosts Immune Reaction in Phase I Trial

An investigatory vaccine from the Baltimore-based Profectus BioSciences is both safe in humans and prompts an immune response to HIV proteins, the Gazette.Net reports. In a Phase I study funded by the National Institute of Allergy and Infectious Diseases, the HIV Vaccine Trials Network tested the vaccine at various dose levels in 60 HIV-negative adults in Philadelphia, San Francisco, Nashville and Decatur, Georgia.

The vaccine proved safe and immunogenic, with the highest dose prompting an immune response to HIV’s gag protein in five out of eight, or 62.5 percent, of study subjects.  That highest dose of the vaccine will go on to further trials.  

The vaccine uses the vesicular stomatitis virus (VSV), a cousin of the rabies virus, as a vector to deliver HIV gag proteins to cells needed to produce an immune response.  Though the VSV can replicate in human cells, it had been weakened enough not to cause illness.

To read the Gazette.Net story, click here.

To read a copy of Profectus BioSciences’ release, click here.

Search: HIV, vaccine, safe, immunogenic, phase I trial, Profectus BioSciences, immune response, proteins, Gazette.Net, HIV Vaccine Trials Network, vesicular stomatis virus, VSV, vector, gag proteins.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (5 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dversescott
    Baltimore
    Maryland


    Loveladyd
    Washington
    DC


    max38man
    Chicago
    Illinois


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.